Open Orphan plc (LON: ORPH) is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.
Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences.
hVIVO is the world leader in the testing of vaccines and antivirals using human challenge study models. It is a trusted partner and industry-leading clinical development services business pioneering human disease models based upon viral challenge.
Run from Europe’s only 24-bedroom quarantine clinic with onsite virology lab in London, hVIVO use human challenge studies to establish early proof-of-concept, hVIVO’s clinical trial platform can accelerate drug and vaccine development in respiratory and infectious disease.
hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics.
Venn Life Sciences
Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise, clinical trial design and execution services. This enables us to create, plan and execute drug and medical device development programs effectively and seamlessly for our clients.
Venn has teams across both early and late phase research, late phase teams specialise in multi-site cross cultural clinical trials with unique knowledge of local and EU regulations. Over Venn’s 25 year history we have built up substantial therapeutic and study experience, contributing to the efficient management of sites, budgets and communication channels with all parties involved. Venn is renowned for its hands-on approach and consistent delivery of high quality work on time and on budget.
Below you will find the 5 day trade history, latest news, interviews and Open Orphan share price.